Phase 1/2a Study of ANPD001 in Parkinson Disease

Inclusion Criteria: * Age 40-75 years of age at time of consent in the trial-ready cohort study ANPD001-01 * Met all eligibility requirements for inclusion in the trial-ready cohort in clinical study ANPD001-01 * Diagnosed with Parkinson Disease at least 4 years ago * Unequivocal motor response to Levodopa Exclusion Criteria: * Prior brain surgery that, in the opinion of the neurologist or neurosurgeon, contraindicates administration of ANPD001 * History of intracranial therapy for PD, including deep brain stimulation (DBS), focused ultrasound (FUS), gene therapy or other biological therapy * History of cognitive impairment or dementia * History of clinically significant Dopa Dysregulation syndrome * History of epilepsy, stroke, multiple sclerosis, poorly controlled or progressive neurological disease (other than PD), or poorly controlled cardiovascular disease * Inability to temporarily stop anticoagulation or antiplatelet therapy for at least 2 weeks * History of malignancy (cerebral or systemic) within the prior 5 years, except treated cutaneous squamous or basal cell carcinomas * Contraindication to MRI / contrast CRT and/or use of contrast agents * Weight \> 300 lbs or Body Mass Index (BMI) \> 35 * Newly diagnosed diabetes (HbA1c \> 7.0%), uncontrolled diabetes \> 8.0% requiring frequent medication changes, or any other acute or chronic medical condition that would significantly increase the risks of a neurosurgical procedure * Pregnancy or lactation * Significant drug-induced dyskinesia (\> 3 for any body part on the Abnormal Involuntary Movement Scale \[AIMS\]) * Male or female with reproductive capacity who is unwilling to use barrier contraception for 3 months post-administration of the investigational product * Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments * Any significant issue raised by the neurologist or neurosurgeon